FRE4 Antibody

What is FRE4 and what biological role does it play in yeast?

FRE4 (Ferric Reductase 4) is a protein encoded by the FRE4 gene (Gene ID: 855797) in Saccharomyces cerevisiae (baker's yeast) . It functions as one of several ferric reductases involved in the iron uptake system of yeast cells. Specifically, FRE4 contributes to the reduction of ferric iron (Fe³⁺) to ferrous iron (Fe²⁺) at the cell surface, which is a crucial step in the high-affinity iron uptake pathway. This reduction process makes iron more soluble and available for transport into the cell through specific transporters.

The FRE4 protein is typically expressed under iron-limited conditions as part of the cellular response to iron starvation. It contains transmembrane domains and is localized to the plasma membrane, where it can access environmental iron sources. Understanding FRE4's function provides insights into how eukaryotic cells regulate metal homeostasis, particularly in challenging environments with limited nutrient availability.

What experimental applications are compatible with FRE4 antibodies?

FRE4 antibodies are versatile tools that can be employed in multiple experimental techniques. Based on available product information, FRE4 antibodies have been validated for applications including ELISA and Western blotting (WB) . These applications allow researchers to detect, quantify, and characterize FRE4 protein in various experimental contexts.

In ELISA applications, FRE4 antibodies can be used to quantitatively measure FRE4 protein levels in yeast lysates or fractionated samples. This technique is particularly valuable for comparative studies examining FRE4 expression under different growth conditions or genetic backgrounds.

For Western blotting, FRE4 antibodies enable researchers to visualize the protein's molecular weight, assess expression levels, and investigate post-translational modifications. This application is especially useful for confirming protein knockdown or overexpression in genetic studies focused on iron metabolism.

Although not explicitly mentioned in the search results, FRE4 antibodies might also be applicable in immunoprecipitation, immunohistochemistry, or flow cytometry, depending on their specific characteristics and validation status.

How should researchers validate the specificity of FRE4 antibodies?

Validation of antibody specificity is crucial for ensuring experimental reliability. For FRE4 antibodies, researchers should implement a multi-faceted validation approach:

• Genetic controls: Compare signal between wild-type yeast and FRE4 knockout strains. A specific antibody will show significantly reduced or absent signal in knockout samples.

• Blocking peptide assays: Pre-incubate the antibody with the immunogen peptide used to generate it. This should neutralize the antibody and eliminate specific signals in subsequent applications.

• Multiple detection methods: Verify consistent results across different techniques (e.g., Western blot, ELISA, immunofluorescence).

• Molecular weight verification: Confirm that the detected protein band appears at the expected molecular weight for FRE4.

• Signal across conditions: Assess signal in conditions known to upregulate or downregulate FRE4 expression (such as iron-limited versus iron-replete media).

This validation approach aligns with current best practices for antibody validation in the research community, which emphasize the importance of using sequence-defined recombinant antibodies that can provide higher reproducibility compared to traditional polyclonal antibodies .

How can researchers utilize FRE4 antibodies to investigate iron metabolism in yeast?

FRE4 antibodies offer powerful tools for investigating the complex dynamics of iron metabolism in Saccharomyces cerevisiae. Researchers can design experiments that leverage these antibodies to:

• Monitor expression patterns: Track FRE4 protein levels under various iron concentrations, oxidative stress conditions, or in different growth phases to map regulatory networks controlling iron homeostasis.

• Study protein-protein interactions: Employ co-immunoprecipitation with FRE4 antibodies to identify interaction partners within the iron regulatory network, potentially revealing novel components or regulatory mechanisms.

• Examine subcellular localization: Use immunofluorescence microscopy with FRE4 antibodies to determine the precise subcellular localization of FRE4 under different environmental conditions, which may provide insights into its functional regulation.

• Assess post-translational modifications: Analyze how phosphorylation, ubiquitination, or other modifications affect FRE4 function by combining FRE4 antibodies with modification-specific detection methods.

• Investigate strain variations: Compare FRE4 expression and localization across different yeast strains to understand evolutionary adaptations in iron acquisition strategies.

These approaches can be particularly valuable when combined with transcriptomic or metabolomic analyses to provide a comprehensive understanding of how FRE4 contributes to iron homeostasis in the broader context of cellular metabolism.

What are potential cross-reactivity concerns with FRE4 antibodies?

When working with FRE4 antibodies, researchers should be aware of several potential cross-reactivity issues:

To address these concerns, researchers should:

• Include appropriate controls in every experiment, including FRE4 deletion strains

• Perform epitope mapping to identify the specific regions recognized by the antibody

• Consider using recombinant antibody technology, which offers improved specificity compared to traditional methods

• Validate results with orthogonal techniques that don't rely on antibody binding

Understanding these potential limitations is crucial for proper experimental design and data interpretation in advanced research applications.

How do recombinant FRE4 antibodies compare to traditional antibodies?

Recombinant antibody technology represents a significant advancement over traditional animal-derived antibodies, offering several advantages particularly relevant to specialized targets like FRE4:

Recent initiatives have prioritized the replacement of ascites-derived and polyclonal antibodies with animal-free, sequence-defined recombinant antibodies to improve both the quality and reproducibility of biomedical research . For FRE4 research specifically, recombinant antibodies can potentially offer superior discrimination between closely related ferric reductase family members, a critical consideration given the sequence similarities within this protein family.

The scientific community has established multifaceted initiatives to accelerate the production and use of animal-free recombinant antibodies, including developing educational materials, fostering public-private partnerships, and increasing funding availability for recombinant antibody development . These advances have particular relevance for specialized research areas like yeast iron metabolism.

What is the recommended protocol for Western blotting with FRE4 antibodies?

Western blotting with FRE4 antibodies requires careful optimization to detect this yeast membrane protein effectively. Here is a recommended protocol based on best practices for yeast proteins:

Sample Preparation:

• Harvest yeast cells during logarithmic growth phase (OD₆₀₀ = 0.6-0.8)

• Wash cells with ice-cold water containing protease inhibitors

• Lyse cells using glass bead disruption in buffer containing:

  • 50 mM Tris-HCl pH 7.5

  • 150 mM NaCl

  • 5 mM EDTA

  • 1% Triton X-100

  • Complete protease inhibitor cocktail

• Clear lysate by centrifugation (10,000 g, 10 minutes, 4°C)

• Determine protein concentration using Bradford or BCA assay

Gel Electrophoresis and Transfer:

• Prepare samples with reducing sample buffer (containing DTT or β-mercaptoethanol)

• Heat samples at 37°C for 10 minutes (avoid boiling, which can cause membrane protein aggregation)

• Load 20-50 μg total protein per lane on 10-12% SDS-PAGE gels

• Transfer to PVDF membrane (recommended over nitrocellulose for hydrophobic proteins)

• Transfer at 100V for 60 minutes in cold transfer buffer containing 20% methanol

Immunoblotting:

• Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Incubate with primary FRE4 antibody at 1:1000 dilution in blocking buffer overnight at 4°C

• Wash 3 times with TBST, 10 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody at 1:5000 in blocking buffer for 1 hour

• Wash 3 times with TBST, 10 minutes each

• Develop using enhanced chemiluminescence (ECL) substrate

• Image using appropriate detection system

Critical Controls:

• Include wild-type and FRE4 knockout samples

• Use anti-PGK1 antibody as loading control (constitutively expressed yeast protein)

• For optimization, test a range of antibody dilutions (1:500 to 1:2000)

This protocol can be adjusted based on specific experimental needs and the particular characteristics of the FRE4 antibody being used.

How should researchers optimize immunoprecipitation protocols with FRE4 antibodies?

Immunoprecipitation (IP) of FRE4 presents specific challenges due to its membrane localization and relatively low abundance under many growth conditions. Here's a methodological approach to optimize IP protocols with FRE4 antibodies:

Pre-Optimization Considerations:

• Expression conditions: Culture yeast under iron-limited conditions to upregulate FRE4 expression

• Antibody suitability: Verify the antibody has been validated for IP applications

• Tag consideration: Consider using epitope-tagged FRE4 constructs if native protein detection proves challenging

Optimized Lysis Protocol:

• Harvest 50-100 ml of yeast culture (OD₆₀₀ = 0.8-1.0)

• Wash cells twice with ice-cold PBS containing 1 mM PMSF

• Resuspend in specialized membrane protein lysis buffer:

  • 50 mM HEPES pH 7.5

  • 150 mM NaCl

  • 1% Digitonin or 1% DDM (n-Dodecyl β-D-maltoside)

  • 5 mM EDTA

  • 1 mM PMSF

  • Protease inhibitor cocktail

• Lyse cells using glass bead disruption (8 cycles of 30 seconds vortexing, 30 seconds on ice)

• Clear lysate by centrifugation (14,000 g, 15 minutes, 4°C)

Immunoprecipitation Procedure:

• Pre-clear lysate with Protein A/G beads (30 minutes, 4°C)

• Incubate 1 mg pre-cleared lysate with 2-5 μg FRE4 antibody overnight at 4°C with gentle rotation

• Add 30 μl Protein A/G magnetic beads and incubate for 3 hours at 4°C

• Wash beads 4 times with wash buffer (lysis buffer with reduced detergent concentration of 0.1%)

• Elute bound proteins with 50 μl 2X SDS sample buffer (without β-mercaptoethanol)

• Add β-mercaptoethanol to eluted samples and heat at 37°C for 10 minutes

• Analyze by SDS-PAGE and immunoblotting

Optimization Parameters:

• Test different detergents (Digitonin, DDM, CHAPS) for optimal membrane protein solubilization

• Vary antibody amounts (1-10 μg per mg lysate)

• Test different incubation times (4 hours vs. overnight)

• Compare direct antibody conjugation to beads versus free antibody approaches

Critical Controls:

• Include "no antibody" control

• Include FRE4 knockout strain as negative control

• Include input, unbound, and IP fractions in analysis

This approach incorporates the specialized handling needed for membrane proteins while maximizing the chances of successful FRE4 immunoprecipitation.

Why might researchers experience weak or no signal when using FRE4 antibodies?

Several factors can contribute to weak or absent signals when working with FRE4 antibodies:

• Expression level variability: FRE4 expression is highly regulated by iron availability. Under iron-replete conditions, FRE4 may be expressed at very low levels or not at all. Ensure cells are grown under iron-limited conditions to induce expression.

• Protein denaturation issues: Membrane proteins like FRE4 can be particularly sensitive to denaturation methods. Avoid boiling samples; instead, heat at 37°C for 10 minutes in sample buffer.

• Extraction inefficiency: Inadequate cell lysis or improper detergent selection may result in poor extraction of membrane-bound FRE4. Consider using specialized membrane protein extraction kits or optimize detergent types and concentrations.

• Antibody specificity limitations: If the antibody recognizes a conformation-dependent epitope, denaturation during SDS-PAGE may eliminate recognition. Consider native PAGE or dot blot approaches.

• Degradation during preparation: FRE4 may be subject to rapid degradation. Ensure all buffers contain appropriate protease inhibitors and maintain samples at 4°C throughout processing.

• Blocking interference: Certain blocking agents may mask the epitope. Test different blocking solutions (milk vs. BSA) if signal is weak.

• Post-translational modifications: Modifications like phosphorylation or glycosylation might interfere with antibody binding. Consider phosphatase or glycosidase treatments to assess this possibility.

For methodological solutions, researchers should:

• Verify antibody viability with positive controls

• Optimize primary antibody concentration (try a range from 1:250 to 1:2000)

• Extend primary antibody incubation time (overnight at 4°C)

• Use signal enhancement systems like biotin-streptavidin amplification

• Consider more sensitive detection reagents (high-sensitivity ECL substrates)

How can researchers leverage advanced technologies for FRE4 antibody development?

Recent advances in antibody technology offer promising approaches for developing next-generation FRE4 antibodies with enhanced specificity and functionality:

• AI-driven antibody design: Platforms like RFdiffusion, recently developed for designing human-like antibodies, could be adapted to create highly specific FRE4 antibodies. This AI approach specializes in building antibody loops—the flexible regions responsible for binding—producing novel antibody blueprints that can bind user-specified targets with high specificity .

• Recombinant antibody development: Rather than relying on traditional animal immunization, recombinant antibody technology allows precise engineering of FRE4-specific antibodies. This approach offers improved reproducibility, consistent performance, and eliminates ethical concerns associated with animal-derived antibodies .

• Single-chain variable fragments (scFvs): The latest RFdiffusion models can generate complete and human-like antibody fragments called scFvs . This format could be particularly valuable for FRE4 detection in complex yeast samples, providing improved penetration into cellular compartments and reduced background.

• Structural biology integration: Combining structural data on FRE4 with computational antibody design can identify optimal epitopes that:

  • Distinguish FRE4 from other FRE family members

  • Target regions exposed in native conformations

  • Focus on conserved regions for cross-species applications

• Nanobody development: Small, single-domain antibody fragments derived from camelid antibodies offer advantages for detecting membrane proteins like FRE4, including better access to sterically restricted epitopes and improved stability .

Researchers interested in developing improved FRE4 antibodies should consider collaborating with specialized laboratories or commercial entities that have implemented these advanced technologies. The Baker Lab, for instance, has made their RFdiffusion software freely available for both non-profit and for-profit research, including drug development .